Ocular involvement in patients with candidemia is classically reported as a significant complication with devastating consequences, a high rate of vision loss, and a potentially fulminant course [1–5]. Several guidelines consistently recommend routine ophthalmoscopy in all candidemic patients [6–9]. That is because when eye involvement is detected, antifungal therapy should include azoles or liposomal amphotericin B, occasionally combined with vitrectomy and/or intraocular antifungal drugs, and the duration of treatment should be extended for 4–6 weeks [6–9].